Markets:

Overview

News

Currencies

International

Treasuries

Viatris Inc. - Common Stock (NQ:VTRS)

17.64 -0.08 (-0.45%)

Delayed Quote Updated: 12:27 PM EDT, Oct 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viatris Inc. - Common Stock

< Previous 1 2

...

16 17 18 19 20 21 22 23 Next >

High Dividend 50: Viatris ↗

March 25, 2022

Viatris is currently offering an above-average dividend yield of 4.4%. The company has posted GAAP losses in each of the last two years but its payout ratio is only 13% using adjusted EPS.

Via Talk Markets

7 Cheap Stocks to Buy Now if You Have $100 to Spend ↗

March 22, 2022

The S&P 500 is off to a forgettable start this year, but that creates multiple buying opportunities if you're looking for cheap stocks.

Via InvestorPlace

35 Generic Drugmakers Sign To Manufacture Low-Cost Version Of Pfizer's COVID Pill ↗

March 17, 2022

Via Benzinga

7 Drug Stocks to Consider After the Viatris Plunge ↗

March 10, 2022

As Viatris and other generic drug makers plunge, what should you buy instead? Consider these seven well-known drug stocks, all of which are good value in what's still a pricey market.

Via InvestorPlace

AbbVie, Alvotech Resolve US Patent Dispute Related To Humira Biosimilar ↗

March 09, 2022

Alvotech Holdings S.A. has entered into a settlement agreement with AbbVie Inc (NYSE: ABBV), allowing Alvotech to market AVT02 (100 mg/mL), its high-...

Via Benzinga

Viatris: Q4 Earnings Insights ↗

February 28, 2022

Viatris (NASDAQ:VTRS) reported its Q4 earnings results on Monday, February 28, 2022 at 06:00 AM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

Earnings Scheduled For February 28, 2022 ↗

February 28, 2022

Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022 ↗

March 01, 2022

Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,...

Via Benzinga

Viatris's Return On Capital Employed Overview ↗

March 01, 2022

Benzinga Pro data, Viatris (NASDAQ:VTRS) reported Q4 sales of $4.34 billion. Earnings fell to a loss of $263.80 million, resulting in a 184.69% decrease from last quarter....

Via Benzinga

Why Viatris Shares Are Trading Lower Today ↗

February 28, 2022

Viatris Inc (NASDAQ: VTRS) is trading lower Monday after the company reported worse-than-expected top-line results for the fourth quarter and issued guidance...

Via Benzinga

67 Biggest Movers From Yesterday ↗

March 01, 2022

Gainers Mullen Automotive, Inc. (NASDAQ: MULN) climbed 145.6% to close at $1.69 on Monday after the company reported progress on solid-state polymer battery pack...

Via Benzinga

Viatris To Pay $264M As EpiPen Antitrust Litigation Settlement: Reuters ↗

February 28, 2022

Viatris Inc (NASDAQ: VTRS), previously known as Mylan, has agreed to pay $264 million to resolve a class-action lawsuit alleging it engaged in a scheme to delay...

Via Benzinga

42 Stocks Moving In Monday's Mid-Day Session ↗

February 28, 2022

Gainers Mullen Automotive, Inc. (NASDAQ: MULN) jumped 74.4% to $1.20 after the company reported progress on solid-state polymer battery pack development. Renewable Energy Group...

Via Benzinga

Mid-Morning Market Update: Markets Open Lower Amid Ongoing Russia-Ukraine Conflict ↗

February 28, 2022

U.S. stocks opened on a downbeat note this morning, amid the ongoing Russia-Ukraine conflict, which has led to increased US sanctions on Russia. Following the market opening...

Via Benzinga

India-Based Biocon To Buy Viatris' Biosimilars Assets In $3.3B Deal ↗

February 28, 2022

Biocon Biologics Ltd has agreed to acquire Viatris Inc's (NASDAQ: VTRS) biosimilars assets for up to $3.335 billion in stock and cash. The deal value...

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

February 28, 2022

On Monday morning, 66 companies achieved new lows for the year. Noteable 52-Week Lows: Gilead Sciences (NASDAQ:GILD) was the largest firm on a market cap basis to set a...

Via Benzinga

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗

February 27, 2022

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...

Via Benzinga

A Bullish Sign Appears On Viatris's Chart ↗

February 16, 2022

If history is any guide, there may be good fortune ahead for shares of Viatris (NASDAQ:VTRS). A so-called "golden cross" has formed on its chart and, not surprisingly, this could...

Via Benzinga

The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, & More ↗

February 06, 2022

Biotech stocks managed to close the week with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid some big pharma earnings. The sector came...

Via Talk Markets

The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More ↗

February 06, 2022

Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big...

Via Benzinga

14 Stocks in the Healthcare Sector ↗

January 21, 2022

Here are 14 companies in the Healthcare Sector that have investment-grade credit ratings of BBB- or better, cash flow yield of 6% or better, future total return of at least 5%.

Via Talk Markets

Viatris Recalls One Batch Of Diabetes Treatment Semglee Citing Missing Label Risks ↗

January 20, 2022

Viatris Inc's (NASDAQ: VTRS) Mylan will pull one batch of non-interchangeable Semglee, also known as insulin glargine injection. The Company cited the risk of the...

Via Benzinga

7 Pharmaceutical Stocks That Could Make You Rich ↗

January 06, 2022

Due to expiring patents and rising competition, successful pharmaceutical stocks need to develop robust drug pipelines. 7 Pharmaceutical Stocks That Could Make You Rich

Via InvestorPlace

7 of the Best Cheap Stocks Under $20 for 2022 to Buy Now ↗

January 03, 2022

These cheap stocks are trading at highly attractive prices and have the potential to break through this year.

Via InvestorPlace

10 Worst Performing S&P 500 Stocks Of 2021 ↗

December 31, 2021

The S&P 500 delivered one of its best years in recent history in 2021, gaining more than 27%. Most U.S. investors had a lot of winners in their portfolios this year, but some...

Via Benzinga

7 of the Best Value Stocks for 2022 to Buy Now ↗

December 15, 2021

Among the best value stocks, these seven provide both deep value and upside potential. Buy now for future gains in 2022.

Via InvestorPlace

Jim Cramer Shares His Warning On Nio, Expresses Support For TJX And More ↗

December 14, 2021

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he doesn’t like NIO Inc. (NYSE:

Via Benzinga

India's Biocon Mulls Merger Of Biosimilar Business With Mylan: Moneycontrol ↗

December 09, 2021

India-based Biocon Ltd is reportedly in talks with generic drugmaker Mylan for a merger of their biosimilar businesses, financial news website ...

Via Benzinga

The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment; Regulatory Setbacks For CTI Biopharma, BioXcel; Favorable Ruling For Viatris In Tecfidera Patent Case ↗

December 01, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Adcom Backing For Oral COVID-19 Antiviral Medication Molnupiravir...

Via Benzinga

Topics Intellectual Property

7 Drug Stocks to Buy Now While They’re Still on Sale ↗

November 30, 2021

Covid-19 stocks soared to unsustainable highs as investors ignored drug stocks with a deep pipeline of products for the decade ahead.

Via InvestorPlace

Topics Supply Chain

< Previous 1 2

...

16 17 18 19 20 21 22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.